BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Top Cited Papers
- 16 September 2011
- journal article
- Published by Elsevier BV in Cell
- Vol. 146 (6), 904-917
- https://doi.org/10.1016/j.cell.2011.08.017
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myelomaLeukemia, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- c-Myc Regulates Transcriptional Pause ReleaseCell, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancerNature Genetics, 2009
- IRF4 addiction in multiple myelomaNature, 2008
- An Extended Transcriptional Network for Pluripotency of Embryonic Stem CellsCell, 2008
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center MalignanciesCancer Cell, 2008
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007